Protein phosphorylation plays critical roles in a variety of intracellular signaling pathways and physiological functions that are controlled by neurotransmitters and neuromodulators in the brain. Dysregulation of these signaling pathways has been implicated in neurodevelopmental disorders, including autism spectrum disorder, attention deficit hyperactivity disorder and schizophrenia. While recent advances in mass spectrometry-based proteomics have allowed us to identify approximately 280,000 phosphorylation sites, it remains largely unknown which sites are phosphorylated by which kinases. To overcome this issue, previously, we developed methods for comprehensive screening of the target substrates of given kinases, such as PKA and Rho-kinase, upon stimulation by extracellular signals and identified many candidate substrates for specific kinases and their phosphorylation sites. Here, we developed a novel online database to provide information about the phosphorylation signals identified by our methods, as well as those previously reported in the literature. The “KANPHOS” (Kinase-Associated Neural Phospho-Signaling) database and its web portal were built based on a next-generation XooNIps neuroinformatics tool. To explore the functionality of the KANPHOS database, we obtained phosphoproteomics data for adenosine-A2A-receptor signaling and its downstream MAPK-mediated signaling in the striatum/nucleus accumbens, registered them in KANPHOS, and analyzed the related pathways.
1 April 2025 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Introduction: Alzheimer's disease (AD) and Parkinson's disease (PD) are neurodegenerative disorders characterized by abnormal protein aggregation, with amyloid beta (Aβ) and α‐synuclein (α‐syn) as key pathological markers. Increasing evidence highlights a pathological interplay between Aβ and α‐syn, exacerbating neurodegeneration in both AD and PD. In this study, we evaluated the effects of reducing amyloid precursor protein (APP) processing on α‐syn pathology using a splice‐switching oligonucleotide (SSO) targeting APP exon 15 in Thy1‐α‐syn transgenic (α‐syn‐tg) mice. Methods: α‐syn‐tg mice received systemic APP SSO treatment. Immunohistochemistry and immunoblotting assessed α‐syn, phosphorylated α‐syn (P‐Syn), and APP C‐terminal fragments (CTFs) in the cortex, hippocampus, and thalamus. Neuronal integrity in different brain regions were examined, and behavioral assessments evaluated cognitive and motor functions. Results: APP SSO treatment significantly reduced α‐syn and P‐Syn in the cortex, hippocampus, and thalamus while also reversing neuronal loss in the hippocampal CA3 region. Interestingly, α‐syn‐tg mice exhibited elevated levels of alternative APP CTFs, which were reduced by APP SSO treatment, implicating APP processing dysregulation in α‐syn pathology. Although behavioral assessments revealed no significant impairments or improvements in female α‐syn‐tg mice. Discussion: Our findings demonstrate that targeting APP reduces α‐syn pathology and rescues neuronal loss, supporting the therapeutic potential of APP modulation in synucleinopathies. While no behavioral changes were observed in transgenic mice, further research exploring different models and conditions may provide additional insights into the full range of therapeutic benefits. Future studies should optimize delivery methods and explore combination therapies to enhance outcomes in neurodegenerative diseases with overlapping proteinopathies. Highlights: APP‐targeting SSO reduces α‐syn and P‐Syn in α‐syn‐tg mice. APP SSO lowers APP CTFs, linking APP processing to α‐syn pathology. Neuronal loss in the hippocampal CA3 region is restored following APP SSO treatment. Behavioral assessments show no significant changes in female α‐syn‐tg mice. Findings support APP modulation as a potential strategy for synucleinopathies.
Effective blood-brain barrier (BBB) penetration is a significant challenge for antisense oligonucleotide (ASO) therapies targeting neurodegenerative diseases. We utilized a peptide (ApoB11) mediated transport delivery of an ASO to the CNS following systemic delivery to reduce expression of targeted transcripts for neurodegenerative diseases. This study evaluates the pharmacokinetics, CNS penetration, and therapeutic efficacy of ApoB11:2'-OMe ASO-α-Syn, an ASO for α-synuclein (α-Syn) suppression in synucleinopathies. After a single intraperitoneal (IP) injection (2 mg/kg) in C57BL/6 mice, ApoB11:ASO-α-Syn showed robust brain penetration, reaching peak concentrations (Cmax = 0.14 nMol/mg) at 1.5 hours and an extended brain half-life (t1/2 = 646.2 hours), indicating prolonged CNS retention. Immunofluorescence confirmed widespread uptake in neurons and endothelial cells. The ASO also accumulated in the liver (Cmax = 419.5 nMol/mg, t1/2 = 104.9 hours), consistent with receptor-mediated uptake. Acute and subacute toxicity studies revealed no systemic toxicity at the highest non-lethal dose (32 mg/kg). In a mouse model of dementia with lewy body (DLB) mice overexpressing human α-Syn, ApoB11:ASO-α-Syn reduced α-Syn mRNA and protein levels in the hippocampus and cortex by ~50% at 16 mg/kg. These results demonstrate that ApoB11 is an effective ASO carrier for CNS delivery, supporting its potential as a therapeutic strategy for synucleinopathies.
Effective blood-brain barrier penetration is a major challenge for antisense oligonucleotide (ASO) therapies targeting neurodegenerative diseases. We utilized an 11-amino acid peptide derived from apolipoprotein B (ApoB11) that binds the low-density lipoprotein receptor to cross the blood-brain barrier, to deliver an ASO systemically to the central nervous system (CNS) and suppress targeted transcripts in neurodegenerative disease models. This study evaluates the pharmacokinetics, CNS penetration, and therapeutic efficacy of ApoB11:2'-O-methyl ASO-α-Syn, an ASO for α-synuclein (α-Syn) suppression in synucleinopathies. After a single intraperitoneal injection (2 mg/kg) in C57BL/6 mice, ApoB11:ASO-α-Syn showed robust brain penetration, reaching peak concentrations (maximum concentration [Cmax] = 0.14 nmol/mg) at 1.5 hours and persisting at high levels over the 96-hour observation period, indicating prolonged CNS retention. Immunofluorescence confirmed widespread uptake in neurons and endothelial cells. The ASO also accumulated in the liver (Cmax = 419.5 nmol/mg, t1/2 = 104.9 hours), consistent with receptor-mediated uptake. Acute and subacute toxicity studies revealed no systemic toxicity at the highest nonlethal dose (32 mg/kg). In a mouse model of dementia with Lewy bodies overexpressing human α-Syn, ApoB11:ASO-α-Syn reduced α-Syn mRNA and protein levels in the hippocampus and cortex by ∼50% at 16 mg/kg, a reduction that is biologically meaningful based on human genetic evidence (SNCA duplications/triplications) and preclinical studies. These results demonstrate that ApoB11 is an effective ASO carrier for CNS delivery, and that partial α-Syn reduction is expected to have disease-relevant effects, supporting its potential as a therapeutic strategy for synucleinopathies. SIGNIFICANCE STATEMENT: This study demonstrates that systemically delivered ApoB11-conjugated antisense oligonucleotides effectively cross the blood-brain barrier, achieve sustained central nervous system retention, and produce a biologically meaningful reduction (∼50%) in α-synuclein expression in a transgenic mouse model of synucleinopathy. These findings highlight a minimally invasive, peptide-mediated strategy for targeting neurodegenerative diseases and overcoming major delivery limitations of antisense oligonucleotide therapies.